AATec Medical and Northway Biotech Form Partnership for ATL-105 Production Development

AATec Medical GmbH and Northway Biotech have announced a partnership aimed at developing and scaling the production process for ATL-105. This innovative therapy, targeting lung diseases like non-cystic fibrosis bronchiectasis, is based on a recombinant version of alpha-1 antitrypsin. The collaboration aims to establish a robust production process, with Northway Biotech leveraging its expertise in biologics manufacturing.

ATL-105 is designed to address significant unmet needs in respiratory diseases, boasting anti-protease, anti-inflammatory, and anti-infective properties that act directly on the lungs. The partnership seeks to progress ATL-105 towards clinical trials, with the potential to redefine treatment for conditions such as chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS).